Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravenous brivaracetam as a replacement for oral brivaracetam in Japanese patients aged 16 and older with partial seizures with or wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial Seizures with or Without Secondary Generalization

Drugs mentioned

• BRIVARACETAM (brivaracetam)

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Partial Seizures With or Without Secondary Generalization, Epilepsy | Phase 3 | Status: COMPLETED